Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia

Tohoku Journal of Experimental Medicine

Volumn 210, Issue 4, 2006, Pages 355-363

  Ishikawa, Izumi ^a   Kato, Chiaki ^b   Harigae, Hideo ^c   Sugawara, Tomohiro ^a   Tomiya, Yasuo ^c   Yamada, Minami ^c   Ishizawa, Kenichi ^c   Kameoka, Junichi ^c   Miyamura, Koichi ^d   Sasaki, Takeshi ^c  

^a Osaki Citizen Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

BCR ABL; Chronic myeloid leukemia; Dose modification; Imatinib mesylate; RQ PCR

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CHIMERIC PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; FEMALE; FLUID RETENTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33845364672     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.210.355     Document Type: Article

References (28)

1. Ali, R., Ozkalemkas, F., Ozcelik, T., Ozkocaman, V., Ozan, U., Kimya, Y., Koksal, N., Gulten, T., Yakut, T. & Tunali, A. (2005) Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res., 29, 971-973.
2. Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., Arber, D.A., Slovak, M.L. & Forman, S.J. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remisssion following imatinib mesylate treatment. Blood, 101, 4701-4707.
3. Bonifazi, F., Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P.C., Steegmann, J.L., Kluin-Nelemans, H.C., Thaler, J., Simonsson, B., Louwagie, A., Reiffers, J., Mahon, F.X., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S. & Baccarani, M.; Europena Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood, 98, 3074-3081.
4. Cortes, J., O'Brien, S. & Kantarjian, H. (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood, 104, 2204-2205.
5. Cortes, J., Talpaz, M., O'Brien, S., Jones, D., Luthra, R., Shan, J., Giles, F., Faderl, S., Verstovsek, S., Garcia-Manero, G., Rios, M.B. & Kantaijian, H. (2005) Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clin. Cancer Res., 11, 3425-3232.
6. Daley, G.Q., Etten, R.A. & Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247, 824-830.
7. Faderl, S., Talpaz, M., Estrov, Z. & Kantarjian, H.M. (1999) Chronic myelogenous leukemia; biology and therapy. Ann. Intern. Med., 131, 207-219.
8. Gabert, J., Beillard, E., Velden, V.H., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cave, H., Pane, F., Aerts, J.L., De Micheli, D., Thirion, X., Pradel, V., Gonzalez, M., Vichmann, S., Malec, M., Saglio, G. & Dongen, J.J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318-2357.
9. Ghanima, W., Kahrs, J., Dahl, T.G., III & Tjonnfjord, G.E. (2004) Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur. J. Haematol., 72, 441-443.
10. Hochhaus, A., Reiter, A., Saussele, S., Reichert, A., Emig, M., Kaeda, J., Schultheis, B., Berger, U., Shepherd, P.C., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood, 95, 62-66.
11. Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Bolton, A.E., Hoomissen, I.C., Goldman, J.M. & Radich, J.P. (2003) International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 349, 1423-1432.
12. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. (1999) Monitoring treatment and survival in chronic myeloid leukemia. J. Clin. Oncol., 17, 1858-1868.
13. Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S. & Talpaz, M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann. Intern. Med., 122, 254-261
14. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S.G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M. & Morra, E.; International STI571 CML Study Group. (2002a) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346, 645-652.
15. Kantarjian, H.M., Talpaz, M., O'Brien, S., Smith, T.L., Giles, F.J., Faderl, S., Thomas, D.A., Garcia-Manero, G., Issa, J.P., Andreeff, M., Kornblau, S.M., Koller, C., Beran, M., Keating, M., Rios, M.B., Shan, J., Resta, D., Capdeville, R., Hayes, K., Albitar, M., Freireich, E.J. & Cortes, J.E. (2002b) Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin. Cancer Res., 8, 2177-2187.
16. Kantarjian, H.M., Cortes, J.E., O'Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., Thomas, D., Jeha, S., Rios, M.B., Letvak, L., Bochinski, K., Arlinghaus, R. & Talpaz, M. (2003) Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 101, 97-100.
17. Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M.B., Shan, J., Letvak, L., Thomas, D., Faderl, S., Ferrajoli, A. & Cortes, J. (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 103, 2873-2878.
18. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247, 1079-1082.
19. Mauro, M.J., Druker, B.J. & Maziarz, R.T. (2004) Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res., 28, Suppl. 1, S71-S73.
20. Merante, S., Orlandi, E., Bernasconi, P., Calatroni, S., Boni, M. & Lazzarino, M. (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica, 90, 979-981.
21. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J.L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J.M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A.E., Capdeville, R. & Druker, B.J. (2003) IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 348, 994-1004.
22. Olavarria, E., Kanfer, E., Szydlo, R., Kaeda, J., Rezvani, K., Cwynarski, K., Pocock, C., Dazzi, F., Craddock, C., Apperley, J.F., Cross, N.C. & Goldman, J.M. (2001) Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 97, 1560-1565.
23. Paschka, P., Muller, M.C., Merx, K., Kreil, S., Schoch, C., Lahaye, T., Weisser, A., Petzold, A., Konig, H., Berger, U., Gschaidmeier, H., Hehlmann, R. & Hochhaus, A. (2003) Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon-alpha. Low levels of residual disease are associated with continuous remission. Leukemia, 17, 1687-1694.
24. Sawyers, C.L. (1999) Chronic myeloid leukemia. N. Engl. J. Med., 340, 1330-1340.
25. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. & Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289, 1938-1942.
26. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., Fischer, T., Deininger, M.W., Lennard, A.L., Hochhaus, A., Ottmann, O.G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F.X., Fernandes-Reese, S., Gathmann, I., Capdeville, R., Kantarjian, H.M. & Sawyers, C.L. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99, 1928-1937.
27. Yamada, M., Miyamura, K., Fujiwara, T., Yokoyama, H., Tomiya, Y., Ishizawa, K., Harigae, H., Kameoka, J. & Sasaki, T. (2004) Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with philadelphia chromosome positive leukemias: Report of 4 cases. Tohoku J. Exp. Med., 204, 79-84.
28. Yoshida, C. & Melo, J.D. (2004) Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol., 79, 420-433.